Market Overview

UPDATE: Wedbush Initiates Coverage on MEI Pharma as Best-in-Class Pracinostat Should Shine

Related MEIP
Events for the Week of Nov. 17-21, 2014
MEI Pharama Reports Improved Response Rates In Phase II Study of Pracinostat In Front Line Acute Myeloid Leukemia

In a report published Thursday, Wedbush analyst David M. Nierengarten initiated coverage on MEI Pharma (NASDAQ: MEIP) with an Outperform rating and $12.00 price target.

In the report, Wedbush noted, “MEI Pharma is developing pracinostat, a best-in-class oral histone deacetylase inhibitor (HDAC inhibitor), in our view, and it is currently in Phase II development for the treatment of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Key top-line data from the company's three Phase II trials of pracinostat in front-line AML, refractory and front-line MDS are likely to read out in mid- to late 2014. Phase I data of pracinostat in combination with azacitidine (Vidaza) generated complete responses in 8 of 10 patients, with 5 of the 10 patients able to receive a bone marrow transplant. This best-in-class response rate is consistent with pracinostat's superior pharmacokinetic/dynamic profile, and our view is that, despite the small number of patients, likely to be continued in the proof-of-concept Phase II studies being conducted.”

MEI Pharma closed on Wednesday at $7.97.

Latest Ratings for MEIP

DateFirmActionFromTo
Oct 2014Roth CapitalMaintains
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy
Jan 2014Brean CapitalInitiates Coverage onBuy

View More Analyst Ratings for MEIP
View the Latest Analyst Ratings

Posted-In: David M. Nierengarten WedbushAnalyst Color Initiation Analyst Ratings

 

Related Articles (MEIP)

Around the Web, We're Loving...

Get Benzinga's Newsletters